Asembia’s Specialty Pharmacy Summit is at the epicenter of the specialty pharmacy industry, providing a unique opportunity for stakeholders throughout to understand challenges, generate solutions
Amneal Pharmaceuticals Methylprednisolone Acetate Injectable Suspension Available Now from Amneal Pharmaceuticals Because consistent supply is what you Demand. Our ever-expanding portfolio includes new dosage forms
Amneal Pharmaceuticals is now shipping Arsenic Trioxide Injection, approved as an Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA). Arsenic
Methylprednisolone Acetate Injectable Suspension Available Now from Amneal Pharmaceuticals Because consistent supply is what you demand. Our ever-expanding portfolio includes new dosage forms and complex
Amneal Launches Taysofy™ (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) – Generic for Taytulla® August 5, 2021 — Amneal Pharmaceuticals has launched
Amneal Receives Approval for Generic TobraDex® – Adding another complex ophthalmic product to the generics portfolio Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”)
Methylprednisolone Acetate Injectable Suspension Available Now from Amneal Pharmaceuticals Because consistent supply is what you demand. Our ever-expanding portfolio includes new dosage forms and complex
Amneal Pharmaceutical is now shipping Etravirine Tablets 100 mg and 200 mg following the June 14th approval of its Abbreviated New Drug Application (ANDA) from
BRIDGEWATER, N.J.– Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the Food and Drug Administration recently accepted Amneal’s 505(b)(2) New Drug
Three capabilities: research and development, safety measures, and a diversified supply chain define why Amneal Pharmaceuticals can bring high-quality generics, specialty, and biosimilar medicines to
